Y. A. Obiedkova
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Y. A. Obiedkova has a total of 8 co-authors. Here are the top co-authors by number of shared publications:
- Anastasiya Nersesyan
Pavlov First Saint Petersburg State Medical University
3 shared publications - M. E. Chernaya
Pavlov First Saint Petersburg State Medical University
3 shared publications - Yurii Sh. Khalimov
Pavlov First Saint Petersburg State Medical University
3 shared publications - Anna R. Volkova
Pavlov First Saint Petersburg State Medical University
2 shared publications - Анна Владимировна Лискер
Pavlov First Saint Petersburg State Medical University
2 shared publications - E. V. Korotkova
Pavlov First Saint Petersburg State Medical University
1 shared publication
Latest Publications
- 18 May 2026
- Published by Endocrinology Research Centre in Diabetes mellitus
- Vol. 29 (2) , 157-168
Non-commercial insulin delivery closed-loop systems: results of comparative research with traditional methods of insulin therapy
BACKGROUND: The problem of achieving target glycemic control in patients with diabetes mellitus type 1 (T1DM) remains relevant. Currently, new, more technologically advanced methods of insulin therapy (IT) are being actively developed — one of them is the IT method of a closed loop (do-it-yourself closed loop system, DIY-CLS). This type of therapy is not registered in Russia, however, patients install these systems themselves, in connection with which it seems important to discuss the principle of DIY-CLS operation, the possibilities and prospects of their use. OBJECTIVE : To evaluate the glycemic control indicators, the frequency of acute complications of diabetes in patients with type 1 diabetes on different types of therapy. MATERIALS AND METHODS : We observed 98 patients who were divided into 3 groups: patients using MII (n=40), patients with CSII (n=40) and patients with DIY-CLS (n=18). All groups were comparable in age, sex and the duration of T1DM history. RESULTS: The majority of patients were women (73.47%), the average age was 33.3±2.4 years, the duration of diabetes was 17.1±2.2 years. It was found that in patients from the DIY-CLS group, compared with the MII and CSII groups, according to continuous glucose monitoring, the time in range was significantly higher, the mean glucose, standard deviation, time above range 10.1–13.9 mmol/l and time above range >13.9 mmol/l were significantly lower. The number of hypoglycemic states and hyperglycemic events leading to the development of ketosis was comparable. CONCLUSION: Glycemic control values were significantly better in patients using DIY-CLS. Patients in the DIY-CLS group more often achieved target time above range and coefficient of variation levels.
- 18 May 2026
- Published by Endocrinology Research Centre in Diabetes mellitus
- Vol. 29 (2) , 157-168
Non-commercial insulin delivery closed-loop systems: results of comparative research with traditional methods of insulin therapy
BACKGROUND: The problem of achieving target glycemic control in patients with diabetes mellitus type 1 (T1DM) remains relevant. Currently, new, more technologically advanced methods of insulin therapy (IT) are being actively developed — one of them is the IT method of a closed loop (do-it-yourself closed loop system, DIY-CLS). This type of therapy is not registered in Russia, however, patients install these systems themselves, in connection with which it seems important to discuss the principle of DIY-CLS operation, the possibilities and prospects of their use. OBJECTIVE : To evaluate the glycemic control indicators, the frequency of acute complications of diabetes in patients with type 1 diabetes on different types of therapy. MATERIALS AND METHODS : We observed 98 patients who were divided into 3 groups: patients using MII (n=40), patients with CSII (n=40) and patients with DIY-CLS (n=18). All groups were comparable in age, sex and the duration of T1DM history. RESULTS: The majority of patients were women (73.47%), the average age was 33.3±2.4 years, the duration of diabetes was 17.1±2.2 years. It was found that in patients from the DIY-CLS group, compared with the MII and CSII groups, according to continuous glucose monitoring, the time in range was significantly higher, the mean glucose, standard deviation, time above range 10.1–13.9 mmol/l and time above range >13.9 mmol/l were significantly lower. The number of hypoglycemic states and hyperglycemic events leading to the development of ketosis was comparable. CONCLUSION: Glycemic control values were significantly better in patients using DIY-CLS. Patients in the DIY-CLS group more often achieved target time above range and coefficient of variation levels.
- 1 January 2025
- Published by Geotar-Media Publishing Group in Endocrinology: News, Opinions, Training
- Vol. 14 (4)
Sarcopenia in young patients: accelerated muscle aging in type 1 diabetes mellitus
- 1 January 2025
- Published by Geotar-Media Publishing Group in Endocrinology: News, Opinions, Training
- Vol. 14 (4)
Sarcopenia in young patients: accelerated muscle aging in type 1 diabetes mellitus
- 1 January 2025
- Published by NP Rusmedical Group in Therapist’s Bulletin
- Vol. 67 (2)
Diabetic cardiovascular neuropathy: causes, consequences and modern treatment strategies
Aim. To study the causes, consequences, and current treatment strategies for the cardiovascular form of diabetic autonomic neuropathy. Key points. Diabetic cardiovascular autonomic neuropathy is a violation of the autonomic innervation of the cardiovascular system and an independent predictor of death in both patients with type 1 and type 2 diabetes mellitus. Chronic hyperglycemia plays a key role in the development of the disease. In the early stages, the parasympathetic division of the autonomic nervous system is affected, which is accompanied by relative sympathicotonia. As the disease progresses, the sympathetic division becomes involved, which leads to myocardial denervation. The diagnosis of diabetic cardiovascular neuropathy is based on a comprehensive examination of the patient and includes the use of the COMPASS-31 (Composite Autonomous Symptom Score 31) questionnaire, assessment of resting heart rate and heart rate variability, and cardiovascular tests. Prevention and treatment of this complication are aimed at reducing the risk of development and progression by improving glycemic control, as well as treating hypertension, dyslipidemia, and lifestyle modifications, including a balanced diet and increased physical activity. Conclusion. Diabetic cardiovascular autonomic neuropathy precedes the development of cardiovascular diseases in type 1 and type 2 diabetes mellitus. The clinical picture of this complication is diverse and inconspicuous, which leads to underestimation of the condition and emphasizes the need for timely diagnosis. Keywords: type 1 diabetes mellitus, type 2 diabetes mellitus, diabetic cardiovascular neuropathy.
- 1 January 2025
- Published by NP Rusmedical Group in Therapist’s Bulletin
- Vol. 67 (2)
Diabetic cardiovascular neuropathy: causes, consequences and modern treatment strategies
Aim. To study the causes, consequences, and current treatment strategies for the cardiovascular form of diabetic autonomic neuropathy. Key points. Diabetic cardiovascular autonomic neuropathy is a violation of the autonomic innervation of the cardiovascular system and an independent predictor of death in both patients with type 1 and type 2 diabetes mellitus. Chronic hyperglycemia plays a key role in the development of the disease. In the early stages, the parasympathetic division of the autonomic nervous system is affected, which is accompanied by relative sympathicotonia. As the disease progresses, the sympathetic division becomes involved, which leads to myocardial denervation. The diagnosis of diabetic cardiovascular neuropathy is based on a comprehensive examination of the patient and includes the use of the COMPASS-31 (Composite Autonomous Symptom Score 31) questionnaire, assessment of resting heart rate and heart rate variability, and cardiovascular tests. Prevention and treatment of this complication are aimed at reducing the risk of development and progression by improving glycemic control, as well as treating hypertension, dyslipidemia, and lifestyle modifications, including a balanced diet and increased physical activity. Conclusion. Diabetic cardiovascular autonomic neuropathy precedes the development of cardiovascular diseases in type 1 and type 2 diabetes mellitus. The clinical picture of this complication is diverse and inconspicuous, which leads to underestimation of the condition and emphasizes the need for timely diagnosis. Keywords: type 1 diabetes mellitus, type 2 diabetes mellitus, diabetic cardiovascular neuropathy.